Pfizer's Duchenne Muscular Dystrophy Treatment Misses Endpoints
By Ben Glickman
Pfizer's gene therapy being developed to treat Duchenne muscular dystrophy missed its primary endpoint in a late-stage trial.
The pharmaceutical company said Wednesday the mini-dystrophin gene therapy didn't meet its primary endpoint of improvement in motor function among boys four to seven years old.
Pfizer said that secondary endpoints, such as 10-meter walk or run velocity and time to rise from the floor velocity, also didn't show a significant difference between those treated with the gene therapy and the placebo in the Phase 3 trial.
Pfizer said that it would continue to closely monitor all participants in the study and was evaluating next steps for the program.
Duchenne is a genetic disease which leads to progressive muscle degeneration and weakness. It primarily affects boys and typically appears in early childhood.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
June 12, 2024 16:56 ET (20:56 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Q2 Earnings Season Begins With the Banks
-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations